EP4720105A1 - Monomères cd40l et leurs procédés d'utilisation dans l'amélioration de til par stimulation ex vivo - Google Patents

Monomères cd40l et leurs procédés d'utilisation dans l'amélioration de til par stimulation ex vivo

Info

Publication number
EP4720105A1
EP4720105A1 EP24816217.4A EP24816217A EP4720105A1 EP 4720105 A1 EP4720105 A1 EP 4720105A1 EP 24816217 A EP24816217 A EP 24816217A EP 4720105 A1 EP4720105 A1 EP 4720105A1
Authority
EP
European Patent Office
Prior art keywords
cd40l
tils
cell
cells
agonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24816217.4A
Other languages
German (de)
English (en)
Inventor
Vince LUCA
Daniel ABATE-DAGA
Renata Ariza Marques ROSSETTI
Patrick Hwu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lee Moffitt Cancer Center and Research Institute Inc
Original Assignee
H Lee Moffitt Cancer Center and Research Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lee Moffitt Cancer Center and Research Institute Inc filed Critical H Lee Moffitt Cancer Center and Research Institute Inc
Publication of EP4720105A1 publication Critical patent/EP4720105A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Selon un aspect, sont divulgués de nouveaux monomères CD40L et des procédés d'utilisation desdits monomères, des constructions trimères desdits monomères, et/ou des constructions multimères comprenant lesdits monomères pour étendre des lymphocytes infiltrant les tumeurs (TIL) in vitro ou ex vivo, lesdits procédés comprenant l'obtention de TIL et la culture des TIL dans des milieux comprenant un ou plusieurs agonistes CD40 (tels que, par exemple, un ligand CD40 [CD40L], un anticorps CD40L multimère et/ou un anticorps anti-CD40). Selon certains aspects, l'agoniste de CD40 peut être surexprimé sur une cellule nourricière TIL.
EP24816217.4A 2023-05-26 2024-05-24 Monomères cd40l et leurs procédés d'utilisation dans l'amélioration de til par stimulation ex vivo Pending EP4720105A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363504462P 2023-05-26 2023-05-26
PCT/US2024/031010 WO2024249307A1 (fr) 2023-05-26 2024-05-24 Monomères cd40l et leurs procédés d'utilisation dans l'amélioration de til par stimulation ex vivo

Publications (1)

Publication Number Publication Date
EP4720105A1 true EP4720105A1 (fr) 2026-04-08

Family

ID=93658643

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24816217.4A Pending EP4720105A1 (fr) 2023-05-26 2024-05-24 Monomères cd40l et leurs procédés d'utilisation dans l'amélioration de til par stimulation ex vivo

Country Status (3)

Country Link
EP (1) EP4720105A1 (fr)
AU (1) AU2024283046A1 (fr)
WO (1) WO2024249307A1 (fr)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050181994A1 (en) * 2003-01-06 2005-08-18 Xencor, Inc. Novel variants of CD40L protein
US20110059137A1 (en) * 2008-03-21 2011-03-10 H. Lee Moffitt Cancer Center And Research Institutute, Inc Chemokine gene-modified cells for cancer immunotherapy
AU2018394238A1 (en) * 2017-12-28 2020-06-18 Lonza Sales Ag Exosomes for immuno-oncology and anti-inflammatory therapy
EP3810641A4 (fr) * 2018-06-19 2022-07-13 H. Lee Moffitt Cancer Center And Research Institute, Inc. Virus oncolytique ou antigène présentant une thérapie anticancéreuse à médiation par des cellules utilisant un interféron de type i et un ligand cd40

Also Published As

Publication number Publication date
WO2024249307A1 (fr) 2024-12-05
AU2024283046A1 (en) 2025-12-18

Similar Documents

Publication Publication Date Title
US12030944B2 (en) Enhanced depletion of targeted cells with CD47 blockade and an immune costimulatory agonist
TWI793325B (zh) 對cd3具特異性之抗體及其用途
CN116096353A (zh) 异二聚体fc融合蛋白的配制品、剂量方案和制造工艺
EP3843759B1 (fr) Utilisation de lymphocytes infiltrant les tumeurs pour traiter les patients souffrant de nsclc réfractaires à un anticorps anti-pd-1
TW202019445A (zh) 嵌合抗原受體療法t細胞擴增動力學及其用途
CN116600805A (zh) 包含抗cd137抗体的组合疗法
EP4720105A1 (fr) Monomères cd40l et leurs procédés d'utilisation dans l'amélioration de til par stimulation ex vivo
US20260062491A1 (en) Cd40l 41bbl bispecific proteins
US20240156910A1 (en) Til enhancement via ex vivo stimulation with cd40 agonists
US20220154144A1 (en) Artificial antigen presenting cells comprising ligands for nkg2d for expanding immune cells for immunotherapy
US20240336893A1 (en) Gene signature predicting tertiary lymphoid structures containing b cells
CA2996167C (fr) Depletion accrue de cellules cibles avec un blocage de cd47 et un agoniste de co-stimulation immunitaire
HK40107843A (en) Use of tumor infiltrating lymphocytes for treating nsclc patients refractory for anti-pd-1 antibody
WO2024151885A1 (fr) Utilisation de til en tant que thérapie de maintenance pour des patients atteints de nsclc qui ont atteint une pr/cr après une thérapie antérieure
HK40126667A (zh) 嵌合抗原和t细胞受体及使用的方法
HK40128442A (zh) 嵌合抗原和t细胞受体及使用的方法
HK40053266A (en) Use of tumor infiltrating lymphocytes for treating nsclc patients refractory for anti-pd-1 antibody
HK40053266B (en) Use of tumor infiltrating lymphocytes for treating nsclc patients refractory for anti-pd-1 antibody

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20251202

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR